



Express Mail No.: EL 477 036 532 US

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Taylor et al.

Serial No.: 09/724,621

Group Art Unit: 1642

Filed: November 28, 2000

Examiner: To Be Assigned

For: METHODS FOR THE PREVENTION
AND TREATMENT OF VIRAL AND
MICROBIAL INFECTIONS USING
ANTI-C3b(i) ANTIBODIES (as amended)

Attorney Docket No.: 9426-056

RECEIVED
MAY 29 2002
TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

JUN 25 2002

TECH CENTER 1600/2900

SIR:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to references CJ listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." A copy of reference CJ is submitted herewith.

Identification of the listed reference is not to be construed an admission of Applicants or Attorneys for Applicants that such reference is available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies the reference cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited" instead of "List of Prior Art Cited."

Applicants respectfully request that the Examiner review the foregoing reference and that the reference be made of record in the file history of the application.

Since this Information Disclosure Statement is being submitted before the mailing date of a first Office Action on the merits, no fee is believed due. However, should the Patent and Trademark Office determine otherwise, please charge any required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date May 23, 2002

Geraldine F. Baldwin 31,232
Geraldine F. Baldwin (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure

By: Jennifer J. Chedler
Reg No. 46,617



RECEIVED

MAY 29 2002

Express Mail N .: EL 477 036 532 US

Sheet 1 of 1

TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)					ATTY. DOCKET NO.		APPLICATION NO.	
					9426-056		09/724,621	
					APPLICANT			
					Taylor et al.			
					FILING DATE		GROUP	
					November 28, 2000		1642	
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
	CJ	McCormick et al. Bispecific antibody (ANTI-C3d/60.3), compensates, in vitro, for the elastase-mediated opsonin-receptor mismatch cystic fibrosis. Immunotechnology Y. 1996, 2(4):303 (abstract)						
EXAMINER					DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

RECEIVED

JUN 25 2002

TECH CENTER 1600/2900